Evidence / Atteritano et al. · 2007
Genistein and cardiovascular risk markers in the parent cohort
Selected research. Study type, product relevance and limitations are shown separately.
Editorial study summary
- Study type
- Biomarker analysis from a randomized, double-blind, placebo-controlled multicentre trial.
- Product relevance
- Ingredient research involving genistein.
- Sample or population
- 389 postmenopausal women with low bone density (198 genistein, 191 placebo).
- Studied dose
- 54 mg/day of genistein or placebo. Both groups received calcium and vitamin D3.
- Duration
- 24 months.
- Finding
- Some glucose, insulin and vascular markers differed from placebo. Blood lipids and endometrial thickness did not differ. Gastrointestinal side effects were reported by 19% versus 8%.
- Limitations
- This report uses the same parent cohort as the bone-density trial. Biomarker changes do not establish fewer cardiovascular events.
- Study quality
- The outcomes, study design and limitations were reviewed. No formal risk-of-bias rating was assigned for this summary.
- Funding and disclosures
- Funding and conflicts for this publication were not verified from the PubMed abstract.
The studies discussed here examine ingredients or other formulations. They do not establish results for this DR.MORGAN finished product.
Licensed product information
S-EQUOL PLUS · NPN 80143622
May reduce severe and frequent menopausal symptoms (such as hot flashes and/or night sweats).